STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in investor meetings at the following investor conferences:

Leerink Partners 2025 Global Healthcare Conference
Tuesday, March 11, 2025

Jefferies Biotech on the Beach Summit
Wednesday, March 12, 2025

Barclays 27^th Annual Global Healthcare Conference
Thursday, March 13, 2025

About Collegium Pharmaceutical, Inc.

Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM^®, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.

Investor Contacts:
Ian Karp
Head of Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.

Danielle Jesse
Director, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Cheryl Wheeler
Head of Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.